Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and is a major cause of cancer-related deaths throughout the world. Adenomatous polyposis coli (*APC*) and *KRAS* mutations are observed in about 90% and 50% of human CRC patients, respectively. These mutations lead to aberrant activation of the Wnt/β-catenin and Ras pathways which play important and interactive roles during initiation and progression of CRCs. Although these relationships between *KRAS* and *APC* mutations in CRC have been illustrated, the mechanism for the cross-talk between the Wnt/β-catenin and the Ras pathways is poorly understood. In previous studies, we discovered that Ras was degraded together with β-catenin upon suppression of Wnt/β-catenin signaling (Jeong *et al*, (2012) Sci Sig 5: ra30, doi: 10.1126/scisignal.2002242). Inhibition of Wnt/β-catenin signaling induced by overexpression of APC or axin resulted in glycogen synthase kinase 3β (GSK3β)-mediated phosphorylation of Ras at threonine-144 and -148, resulting in polyubiquitin-dependent proteasomal degradation of phosphorylated Ras through recruitment of β-TrCP E3 linker. Both β-catenin and Ras proteins are frequently co-stabilized in CRCs in both mice and humans. The increased mutant K-Ras and β-catenin levels that occur concomitantly with APC loss play critical roles in growth and metastasis of CRC.

Based on these results, we screened a small molecule library and identified KY1220, a compound that was shown in our recent study to induce both β-catenin and Ras degradations via inhibition of the Wnt/β-catenin signaling. By synthesis of its derivatives, we obtained KYA1797K which has improved functionalities in the degradation of both β-catenin and Ras as well as in suppression of CRC cell proliferation.

We also found that KYA1797K binds to the regulators of G-protein signaling (RGS) domain of axin. Analysis of an axin mutant with an alanine replacement at lysine-147 in the RGS domain revealed that this substitution abolished the effects of KYA1797K on the degradation of both β-catenin and Ras, indicating that this residue is essential for KYA1797K binding and subsequent destabilization of both β-catenin and Ras. Furthermore, KYA1797K induced formation of the β-catenin destruction complex, which activates GSK3β, leading to phosphorylation of both β-catenin and Ras ([Fig. 1](#F001){ref-type="fig"}). The β-TrCP E3-linker was recruited to the phosphorylated β-catenin and Ras, which were subjected to destabilization via polyubiquitinlation-dependent proteasomal degradation ([Fig. 1](#F001){ref-type="fig"}). This destabilization of β-catenin and Ras by KYA1797K reduced proliferation of various CRC cells harboring APC and KRAS mutations. In addition, administration of KYA1797K efficiently suppressed tumor growth in mouse xenografts of CRC cells expressing *APC* and *KRAS* mutations and in genetically engineered *Apc^min/＋^*/*Kras^G12D^LA2* mice. Collectively, these results indicate that degradation of β-catenin and Ras by this small molecule-based approach would be a potential strategy for treatment of CRCs with activated Wnt/β-catenin and Ras pathways.

![A Schematic model for the degradation of β-catenin and Ras by KYA1797K. Binding of KYA1797K with the axin-RGS domain enhances formation of the β-catenin destruction complex, which activates GSK3β. The activated GSK3β phosphorylates both β-catenin and Ras and these phosphorylated proteins undergo β-TrCP E3 linker-mediated polyubiquitinylation-dependent proteasomal degradation.](BMB-49-455-g001){#F001}

Because KYA1797K destabilizes Ras, as well as β-catenin, our small molecule-based approach may offer a new strategy for the development of Ras-targeting therapeutics. Ras has been considered an attractive target for anti-cancer drug development. Although significant efforts have been made, most of the approaches to control Ras have been unsuccessful. However, the need for Ras-targeting agents is increasing because patients harboring *KRAS* mutations show unresponsiveness to current therapeutics such as anti-epidermal growth factor receptor (EGFR) agents. Therefore, the small molecules that degrade both β-catenin and Ras and their improved derivatives may not only be applicable for CRC patients harboring *KRAS* mutations, but also for those who are unresponsive to the EGFR-targeting therapies due to *KRAS* mutations.

In conclusion, our small molecule-based approach can be used as a potential strategy for the development of anti-cancer drugs for the treatment of CRC and other cancers with activated Wnt/β-catenin and/or Ras pathways.
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